| 摘要: |
| 癫是一种由不同原因引起的慢性脑部疾患,目前临床抗癫药物(AEDs)种类繁多,但仍有约30%癫患者性发作不能控制,需多种AEDs联合应用或加用新的AEDs。新的AEDs应具有好的临床效能、耐受性及药代动力学和最小的不良反应。目前新一代AEDs包括20种,大多为现有AEDs的衍生物,其中Brivaracetam(BRI)为左乙拉西坦(LEV)的衍生物。本文将从LEV及其衍生物BRI的作用机制、临床应用、耐受性、药理及毒理、不良反应等方面对AEDs发展趋势作一综述。 |
| 关键词: 癫 抗癫药物 左乙拉西坦 Brivaracetam |
| DOI：10.3724/SP.J.1008.2011.0550 |
| 投稿时间：2010-05-15修订日期：2010-11-13 |
| 基金项目: |
|
| From levetiracetam to brivaracetam: development of antiepileptic drugs |
| DUAN Xiao-ling,XIAO Nong * |
| (Rehabilitation Center of Children’s Hospital, Chongqing Medical University, Chongqing 400014, China) |
| Abstract: |
| Epilepsy is a chronic neurological disorder with different etiologies.Despite of many antiepileptic drugs (AEDs) used in clinical treatment, about 30% of the patients have uncontrolled onset, and combined use of different AEDs or new AEDs are needed. The new AEDs should have satisfactory clinical efficacy, tolerability and pharmacokinetic properties, and minimal adverse effects.By now there have been about 20 novel AEDs; most of them are derivatives or analogues of current AEDs. Brivaracetam (BRI) is the derivative of levetiracetam(LEV). This review summarizes the mechanisms of action, pharmacokinetic profiles, tolerability, pharmacology and toxicology, and side effects of LEV and its derivative BRI. |
| Key words: epilepsy antiepileptic agents levetiracetam Brivaracetam |
